MCID: ADR016
MIFTS: 61

Adrenal Cortical Carcinoma malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Nephrological diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Carcinoma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 27GTR, 30ICD10, 31ICD10 via Orphanet, 36MalaCards, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Adrenal Cortical Carcinoma:

Name: Adrenal Cortical Carcinoma 52 36 11 12
Adrenocortical Carcinoma 36 11 48 54 70 27 39 13 68
Adrenocortical Carcinoma, Hereditary 52 68
Hereditary Adrenocortical Carcinoma 70 27
Pediatric Adrenocortical Carcinoma 70 27
Carcinoma of the Adrenal Cortex 11 27
Malignant Neoplasm of Adrenal Cortex 68
 
Adrenocortical Carcinoma, Pediatric 68
Carcinoma Adrenocortical 50
Aplasia Cutis Congenita 68
Adrenocortical Cancer 50
Adcc 70
Acc 48

Characteristics:

Orphanet epidemiological data:

54
adrenocortical carcinoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood

HPO:

64
adrenal cortical carcinoma:
Inheritance: autosomal recessive inheritance

Classifications:



External Ids:

OMIM52 202300
Disease Ontology11 DOID:3948
MeSH39 D018268
NCIt45 C9325
Orphanet54 ORPHA1501
SNOMED-CT62 2227007, 255035007
MESH via Orphanet40 D018268
ICD10 via Orphanet31 C74.0
UMLS via Orphanet69 C0206686
ICD1030 C74.0

Summaries for Adrenal Cortical Carcinoma

About this section
NIH Rare Diseases:48 Adrenocortical carcinoma is a rare cancer affecting the outside of the adrenal glands (adrenal cortex). These glands are on top of each kidney and are responsible for producing certain hormones and keeping blood pressure at normal levels. Adrenocortical carcinoma is relatively frequent in children compared to many other cancers, although the cancer may also affect adults. Girls are more often affected than boys. Symptoms of adrenocortical carcinoma may include pain in the abdomen, hypertension, weight gain, frequent urination and possibly deepening of the voice. These symptoms are due to the tumors causing excess secretion of hormones from the adrenal glands. Adrenocortical carcinoma may develop by chance alone, but at least 50% of the cancers are thought to be hereditary. There are a number of genes that have changes (mutations) that can cause an adrenocortical carcinoma, including TP53 and IGF2. There have been reports of both autosomal dominant inheritance and autosomal recessive inheritance. An adrenocortical carcinoma is diagnosed based on urine tests for abnormal levels of cortisol, the hormone released by the adrenal glands. Blood tests can also be conducted to measure levels of potassium and sodium in the blood. A CT scan or MRI may be used to search for a visible tumor in the adrenal cortex. Treatment options include surgical removal of the tumor, which is important to achieve a good long-term outlook. Chemotherapy, specifically a drug called mitotane, can be used to try to remove any remaining cancer after surgery.  Last updated: 9/8/2016

MalaCards based summary: Adrenal Cortical Carcinoma, also known as adrenocortical carcinoma, is related to adrenocortical carcinoma with pure aldosterone hypersecretion and li-fraumeni syndrome, and has symptoms including adrenocortical carcinoma and flank pain. An important gene associated with Adrenal Cortical Carcinoma is TP53 (Tumor Protein P53), and among its related pathways are Diseases of metabolism and Ovarian steroidogenesis. Affiliated tissues include cortex, adrenal cortex and adrenal gland, and related mouse phenotypes are Decreased shRNA abundance (Z-score < -2) and adipose tissue.

Disease Ontology:11 An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has material basis in abnormally proliferating cells derives from epithelial cells.

UniProtKB/Swiss-Prot:70 Adrenocortical carcinoma: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith-Wiedemann syndrome and Li-Fraumeni syndrome.

OMIM:52 Adrenocortical carcinoma (ADCC) is a rare but aggressive childhood tumor, representing about 0.4% of childhood tumors,... (202300) more...

Wikipedia:71 Adrenocortical carcinoma, also adrenal cortical carcinoma (ACC) and adrenal cortex cancer, is an... more...

Related Diseases for Adrenal Cortical Carcinoma

About this section

Diseases related to Adrenal Cortical Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 146)
idRelated DiseaseScoreTop Affiliating Genes
1adrenocortical carcinoma with pure aldosterone hypersecretion11.9
2li-fraumeni syndrome11.5
3adrenal carcinoma11.5
4aplasia cutis congenita, nonsyndromic11.4
5salivary gland adenoid cystic carcinoma11.1
6agenesis of the corpus callosum with peripheral neuropathy11.0
7corpus callosum agenesis11.0
8proud syndrome10.9
9adrenal cortical adenocarcinoma10.8
10ceruminous carcinoma10.8
11acinar cell carcinoma of pancreas10.8
12acetyl-coa carboxylase deficiency10.7
13aicardi syndrome10.7
14aplasia cutis congenita with intestinal lymphangiectasia10.7
15aplasia cutis congenita10.7
16adult ependymoblastoma10.7IGF2, TP53
17substance abuse10.7HSD11B2, TP53
18ovary mixed epithelial carcinoma10.6CHGA, SYP
19esophagus small cell carcinoma10.6CHGA, SYP
20frontal sinus inverted papilloma10.6CHGA, TP53
21lice infestation10.6CHGA, SYP
22childhood malignant schwannoma10.6CHGA, SYP
23microglandular adenosis of breast10.6CHGA, SYP
24clear cell adenoma10.6CHGA, SYP
25focal facial dermal dysplasia10.6CHGA, SYP
26punctate porokeratosis10.6CHGA, SYP
27osteoblastoma10.6CHGA, SYP
28urethra adenocarcinoma10.6CHGA, SYP
29esophagus adenocarcinoma10.6CHGA, SYP
30fraxf syndrome10.6CHGA, SYP
31froelich syndrome10.5CHGA, SYP
32cerebellar vermis medulloblastoma10.5CHGA, CYP17A1, TP53
33brain glioma10.5SYP, TP53
34vulvar benign neoplasm10.5SYP, TP53
35drug-induced vasculitis10.5NR0B1, NR5A1
36mixed endometrial stromal and smooth muscle tumor10.5CHGA, SYP, TP53
37brainstem intraparenchymal clear cell meningioma10.5SYP, TP53
38diencephalic astrocytomas10.5CHGA, SYP, TP53
39classic pulmonary blastoma10.5CHGA, SYP, TP53
40pancreatic agenesis10.5CHGA, SYP, TP53
41mixed epithelial stromal tumour10.5CHGA, SYP, TP53
42hypersensitivity reaction type ii disease10.5IGF2, SYP, TP53
43restrictive cardiomyopathy10.5CHGA, SYP, TP53
44lumbar plexus neoplasm10.5CHGA, SYP
45cell type cancer10.5CHGA, SYP, TP53
46neurodermatitis10.5CHGA, SYP, TP53
47richter's syndrome10.5CHGA, SYP, TP53
48yolk sac tumor of central nervous system10.5SYP, TP53
49brown-vialetto-van laere syndrome10.4CHGA, SYP, TP53
50tooth disease10.4CYP11A1, CYP17A1, NR5A1

Graphical network of the top 20 diseases related to Adrenal Cortical Carcinoma:



Diseases related to adrenal cortical carcinoma

Symptoms & Phenotypes for Adrenal Cortical Carcinoma

About this section

Symptoms by clinical synopsis from OMIM:

202300

Clinical features from OMIM:

202300

Human phenotypes related to Adrenal Cortical Carcinoma:

 64
id Description HPO Frequency HPO Source Accession
1 adrenocortical carcinoma64 HP:0006744

UMLS symptoms related to Adrenal Cortical Carcinoma:


flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-589.5CYP11A1, CYP21A2, NR5A1, TP53

MGI Mouse Phenotypes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.4CYP11B2, CYP19A1, MC2R, POMC, PRKAR1A, TP53
2MP:00020068.3HSD11B2, INHA, NR0B1, POMC, PRKAR1A, TP53
3MP:00028738.0CYP11A1, CYP19A1, HSD11B2, INHA, NR5A1, PRKAR1A
4MP:00053677.9CHGA, CYP11B1, CYP11B2, CYP19A1, HSD11B2, IGF2
5MP:00053867.3CYP11A1, CYP11B1, CYP17A1, CYP19A1, HSD11B2, IGF2
6MP:00053897.0CHGA, CYP11A1, CYP11B2, CYP17A1, CYP19A1, IGF2
7MP:00053856.4CHGA, CYP11B1, CYP11B2, CYP19A1, HSD11B2, IGF2
8MP:00107686.3BMS1, CHGA, CYP11A1, CYP11B1, CYP17A1, HSD11B2
9MP:00053786.2CHGA, CYP11A1, CYP11B1, CYP11B2, CYP19A1, IGF2
10MP:00053796.0CHGA, CYP11A1, CYP11B1, CYP11B2, CYP19A1, IGF2
11MP:00053765.3CHGA, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1

Drugs & Therapeutics for Adrenal Cortical Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Bexxar16 44 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
FDA Label: Bexxar
Disease/s that Drug Treats:Non-Hodgkin's Lymphoma
Indications and Usage:16 BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directedradiotherapeutic antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed nonHodgkin'slymphoma who have progressed during or after rituximab therapy,including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1)Determination of the effectiveness of the BEXXAR therapeutic regimen isbased on overall response rates in patients whose disease is refractory tochemotherapy and rituximab. The effects of the BEXXAR therapeuticregimen on survival are not known. (1.1)Important Limitation of Use BEXXAR therapeutic regimen is only indicated for a single course oftreatment and is not indicated for a first-line treatment. (1.2)
DrugBank Targets:14 1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10.Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: CD20
Action: cytotoxic antibody
FDA: Tositumomab binds specifically to an epitope within the extracellular domain of the586 CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B lymphocytes587 to mature B lymphocytes) and on B-cell non-Hodgkin's lymphomas. The CD20 molecule is not588 shed from the cell surface and is not internalized following antibody binding. The BEXXAR589 therapeutic regimen induces cell death by emitting ionizing radiation to CD20-expressing590 lymphocytes or neighboring cells. In addition to cell death mediated by the radioisotope, other591 possible mechanisms of action include antibody-dependent cellular cytotoxicity, complement-592 dependent cytotoxicity, and CD20-mediated apoptosis.
2
Perjeta16 44 PERTUZUMAB Genentech June 2012
FDA Label: Perjeta
Disease/s that Drug Treats:HER2+ metastatic breast cancer
Indications and Usage:16 PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment ofpatients with HER2-positive metastatic breast cancer (MBC) who havenot received prior anti-HER2 therapy or chemotherapy for metastaticdisease. (1.1) Use in combination with trastuzumab and docetaxel as neoadjuvanttreatment of patients with HER2-positive, locally advanced,inflammatory, or early stage breast cancer (either greater than 2 cm indiameter or node positive) as part of a complete treatment regimen forearly breast cancer. This indication is based on demonstration of animprovement in pathological complete response rate. No data areavailable demonstrating improvement in event-free survival or overallsurvival. (1.2, 2.1, 14.2)Limitations of Use: The safety of PERJETA as part of a doxorubicin-containing regimenhas not been established. The safety of PERJETA administered for greater than 6 cycles forearly breast cancer has not been established.
DrugBank Targets:14 1. Receptor tyrosine-protein kinase erbB-2
Mechanism of Action:16 
Target: mitogen-activated protein (MAP) kinase, phosphoinositide 3-kinase445 (PI3K)
Action: inhibitor of ligand-initiated intracellular signaling
FDA: Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways, mitogen-activated protein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC). While pertuzumab alone inhibited the proliferation of human tumor cells, the combination of pertuzumab and trastuzumab augmented anti-tumor activity in HER2-overexpressing xenograft models.
3
Unituxin16 44 DINUTUXIMAB United Therapeutics March 2015
FDA Label: Unituxin
Disease/s that Drug Treats:pediatrics with high-risk neuroblastoma
Indications and Usage:16 Unituxin is a GD2-binding monoclonal antibody indicated, incombination with granulocyte-macrophage colony-stimulating factor(GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for thetreatment of pediatric patients with high-risk neuroblastoma whoachieve at least a partial response to prior first-line multiagent,multimodality therapy. (1)
DrugBank Targets:14 1. Ganglioside GD2
Mechanism of Action:16 
Target: GD2
Action: inducer of cell lysis through ADCC and CDC
FDA: Dinutuximab binds to the glycolipid GD2. This glycolipid is expressed on neuroblastoma cellsand on normal cells of neuroectodermal origin, including the central nervous system andperipheral nerves. Dinutuximab binds to cell surface GD2 and induces cell lysis of GD2-expressing cells through antibody-dependent cell-mediated cytotoxicity (ADCC) andcomplement-dependent cytotoxicity (CDC).
4
Portazza16 NECITUMUMAB Eli Lilly November 2015
FDA Label: Portazza
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:16 PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. (1.1) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. (1.2, 5.6, 14.2)
DrugBank Targets: -
Mechanism of Action:16 
Target: EGFR
Action: blocks the binding of EGFR to its ligands
FDA: Necitumumab is a recombinant human lgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. Expression and activation of EGFR has been correlated with malignant progression, induction of angiogenesis, and inhibition of apoptosis. Binding of necitumumab induces EGFR internalization and degradation in vitro. In vitro, binding of necitumumab also led to antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. In in vivo studies using xenograft models of human cancer, including non-small cell lung carcinoma, administration of necitumumab to implanted mice resulted in increased antitumor activity in combination with gemcitabine and cisplatin as compared to mice receiving gemcitabine and cisplatin alone.

Drugs for Adrenal Cortical Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 161)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Epinephrineapproved, vet_approvedPhase 3, Phase 2, Phase 193351-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
2
MitotaneapprovedPhase 3, Phase 21053-19-04211
Synonyms:
(+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane
(2,4'-Dichlorodiphenyl)dichloroethane
(o,p)-DDD
1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane
1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane
1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane
1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane
1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene
1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane
2,4'-Ddd
2,4'-Dichlorodiphenyldichloroethane
2,4'-Dichlorophenyldichlorethane
2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane
2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
25925_FLUKA
25925_SIGMA
35485_FLUKA
35485_RIEDEL
49015_SUPELCO
53-19-0
AC1L1HNV
AC1Q3H13
AI3-07575
BRN 2056007
BSPBio_002517
Bristol Myers Squibb Brand of Mitotane
Bristol-Myers Squibb Brand of Mitotane
C 3010
C14H10Cl4
CB 313
CB-313
CB313
CCRIS 4397
CHEMBL1670
CID4211
Chloditan
Chlodithan
Chlodithane
D00420
D008939
DB00648
DivK1c_000703
EINECS 200-166-6
EU-0100251
Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8CI)
HMS1923K19
HMS2091E07
HMS502D05
HSDB 3240
IDI1_000703
KBio1_000703
KBio2_002505
KBio2_005073
KBio2_007641
KBio3_002017
 
KBioGR_001237
KBioSS_002513
Khloditan
Khlodithan
LS-185
Lopac0_000251
Lysodren
Lysodren (TN)
MLS001335899
MLS001335900
MLS002152914
MLS002153233
Mitotan
Mitotane
Mitotane (JAN/USP/INN)
Mitotane [USAN:INN:JAN]
Mitotano
Mitotano [INN-Spanish]
Mitotanum
Mitotanum [INN-Latin]
MolPort-001-779-578
Mytotan
NCGC00015226-03
NCGC00015226-09
NCGC00091374-01
NCGC00091374-02
NCGC00091374-03
NCGC00091374-04
NCGC00091374-05
NCGC00091374-06
NCI-C04933
NCI60_003688
NINDS_000703
NSC 38721
NSC-38721
NSC38721
PS694_SUPELCO
Prestwick_75
SMR000326696
SPBio_000792
SPECTRUM330082
ST51016017
Spectrum2_000916
Spectrum3_000869
Spectrum4_000709
Spectrum5_002060
Spectrum_001959
UNII-78E4J5IB5J
WLN: GYGYR BG&R DG
mitotane
o,p'-DDD
o,p'-Dichlorodiphenyldichloroethane
o,p'-TDE
o,p-DDD
o,p-Tde
ortho,para DDD
ortho,para-DDD
3
StreptozocinapprovedPhase 3918883-66-429327
Synonyms:
-nitrosomethylharnstoff
1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
18883-66-4
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose
2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose
2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose
2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
AB00513906
AC1L1H7V
Ambap18883-66-4
BCBcMAP01_000142
BPBio1_000754
BSPBio_000684
BSPBio_002734
C07313
CHEBI:9288
CHEMBL1603
CID29327
D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)- (9CI)
D05932
DB00428
DivK1c_000531
Estreptozocina
HMS1921A07
HMS2092I09
HMS501K13
IDI1_000531
KBio1_000531
KBio2_001440
KBio2_004008
KBio2_006576
KBio3_001954
KBioGR_001768
KBioSS_001440
MolPort-003-665-493
N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine
N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
 
N-D-Glucosyl-(2)-N'-nitrosomethylurea
N-D-Glucosyl-(2)-n'
N-D-Glucosyl-(2)-n'-nitrosomethylurea
NCGC00178500-01
NCGC00178500-02
NINDS_000531
Prestwick3_000732
S0130_SIAL
S0130_SIGMA
S1312_Selleck
SMP1_000282
SPBio_000243
SPECTRUM1500543
STREPTOZOTOCIN
STRZ
Spectrum2_000062
Spectrum3_001087
Spectrum4_001244
Spectrum5_001047
Spectrum_000960
Streptozocin
Streptozocin (USAN/INN)
Streptozocin, Zanosar, STZ,Streptozotocin
Streptozocine
Streptozocine [INN-French]
Streptozocinium
Streptozocinium [Latin]
Streptozocinum
Streptozocinum [INN-Latin]
Streptozotocin
UNII-5W494URQ81
ZINC03977737
Zanosar
Zanosar (TN)
alkylating agent
binds to DNA
streptozocin
streptozosin
4
EtoposideapprovedPhase 3, Phase 2123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
5
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
6
Hydrocortisoneapproved, vet_approvedPhase 3, Phase 264050-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
7
EtomidateapprovedPhase 2, Phase 3, Phase 16333125-97-236339, 667484
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Etomidate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
(d)-Etomidate
1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester
1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester
15301-65-2
1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
33125-97-2
AC-5898
AC1L1VLF
AC1Q34BV
AC1Q64LP
AKOS000548952
Absele
Amidate
Amidate (TN)
Amidate (pharmaceutical)
Amidate, Etomidate
BAS 01947657
BRN 0665833
C07522
C14H16N2O2
CHEBI:129025
CHEMBL23731
CID36339
CPD000010931
D-Etomidate
D005045
D00548
 
DB00292
EINECS 251-385-9
Ethnor
Ethomidate
Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Etomidate
Etomidate (USAN/INN)
Etomidate [USAN:BAN:INN]
Etomidato
Etomidato [INN-Spanish]
Etomidatum
Etomidatum [INN-Latin]
Etomidic acid
HMS1571A04
HMS1612G10
HMS2093P17
Hypnomidate
LS-78232
MLS000034952
MLS001240191
MolPort-000-917-569
Prestwick0_001041
Prestwick1_001041
Prestwick2_001041
R 16659
R 26490
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-26490
R26490
Radenarcon
Radenarkon
S1329_Selleck
SAM002548930
SBB066197
SMR000010931
SPBio_002901
UNII-Z22628B598
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
8
Doxorubicinapproved, investigationalPhase 3, Phase 2, Phase 1171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
9
Mifepristoneapproved, investigationalPhase 314884371-65-355245
Synonyms:
(11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
11beta-(4-Dimethyl-?amino)-?phenyl-17beta-hydroxy-17-(1-propynyl)-?estra-4,9-dien-3-one
11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
122742-25-0
17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
404951-53-7
83203-42-3
84371-65-3
AC1L1IOO
AC1O62SB
Ambap84371-65-3
BIDD:PXR0123
BPBio1_000262
BRD-K37270826-001-04-5
BRN 5779404
BSPBio_000238
C-1073
C07652
C29H35NO2
CHEBI:50692
CHEMBL157
CHEMBL356066
CI-1073
CID55245
CID6445533
CPD000058481
Contragest Brand of Mifepristone
Corlux
D00585
D015735
DB00834
Dacinostat
Danco Brand of Mifepristone
EC-000.2469
EU-0100801
Exelgyn Brand of Mifepristone
FT-0082666
HMS1568L20
HMS2052L05
HMS2090L22
HSCI1_000369
HSDB 6841
I14-11726
LAQ-824
LS-192513
LS-64723
Lopac0_000801
M 8046
 
M8046_SIGMA
MLS000069785
MLS001074115
Mifegyne
Mifeprex
Mifeprex (TN)
Mifepriston
Mifepristona
Mifepristona [Spanish]
Mifepristone (USAN/INN)
Mifepristone Contragest Brand
Mifepristone Danco Brand
Mifepristone Exelgyn Brand
Mifepristone [USAN:INN:BAN]
Mifepristonum
Mifepristonum [Latin]
Mifépristone
MolPort-003-849-222
NCGC00025179-05
NCGC00025179-08
NCGC00179632-01
NVP-LAQ 824
NVP-LAQ824
NVP-LAQ824, Dacinostat, LAQ824
Pictovir
Pictovir (TM)
Prestwick0_000299
Prestwick1_000299
Prestwick2_000299
Prestwick3_000299
Prestwick_570
R 38486
R-38486
R38486
RU 38486
RU 486
RU 486-6
RU-38486
RU-486
RU-486, MIFEPRISTONE
RU-486, RU-38486, Mifegyne, Mifeprex, Mifepristone
RU38486
RU486
S1095_Selleck
S1611_Selleck
SAM001246881
SMR000058481
SPBio_002457
Spectrum5_002045
TL8005515
UNII-320T6RNW1F
UNII-V10P524501
VGX-410
VGX-410C
VX-410
ZINC03831128
ZK 98296
ZK-98296
ZK98296
mifepristone
nchembio.313-comp12
10
CisplatinapprovedPhase 3, Phase 2, Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
11
IsotretinoinapprovedPhase 31184759-48-25538, 5282379
Synonyms:
(13-cis)-Retinoate
(13-cis)-Retinoic acid
(13cis)-retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7E,9E,11E,13Z)-retinoic acid
(7e,9e,11e,13Z)-Retinoic acid
13 Cis-Retinoic Acid
13 cis retinoic acid
13-RA
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin A acid
13-cis-Vitamin a acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-Isotretinoin
CPD000471891
Claravis
D00348
D015474
EINECS 225-296-0
EU-0101081
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
Isotretinoin
Isotretinoin (USP)
Isotretinoin Retinoic acid
 
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoin [USAN:BAN:INN]
Isotretinoin [USAN:INN:BAN]
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
LS-143465
Lopac0_001081
MLS001074662
MolPort-003-666-394
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin A acid
Neovitamin a acid
Prestwick2_000256
Prestwick3_000256
Prestwick_642
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 4-3780
Ro 43780
Ro-4-3780
Ro-43780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
SPECTRUM1502013
Sotret
Sotret (TN)
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
cis-RA
cis-Retinoate
cis-Retinoic acid
isotretinoino
12
LenograstimapprovedPhase 31202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
13
Tretinoinapproved, investigational, nutraceuticalPhase 3220302-79-45538
Synonyms:
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-trans Retinoic Acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
14
DoxilApproved June 1999Phase 3, Phase 2, Phase 1171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
15Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 15420
16RacepinephrinePhase 3, Phase 2, Phase 1933
17Epinephryl boratePhase 3, Phase 2, Phase 1933
18Antineoplastic Agents, HormonalPhase 3, Phase 25407
19Liver ExtractsPhase 3, Phase 2, Phase 1, Early Phase 13868
20Hydrocortisone 17-butyrate 21-propionatePhase 3, Phase 2640
21Insulin, Globin ZincPhase 3, Phase 24523
22Hydrocortisone acetatePhase 3, Phase 2640
23Hormone AntagonistsPhase 3, Phase 212778
24HormonesPhase 3, Phase 213979
25Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 212767
26Melanocyte-Stimulating HormonesPhase 3132
27Hypnotics and SedativesPhase 2, Phase 3, Phase 12485
28insulinPhase 3, Phase 24524
29Etoposide phosphatePhase 3, Phase 21232
30Adjuvants, ImmunologicPhase 3, Phase 2, Phase 12484
31MitogensPhase 3, Phase 21526
32Luteolytic AgentsPhase 3294
33Cortisol succinatePhase 3, Phase 2640
34Anesthetics, GeneralPhase 3, Phase 2, Phase 12787
35Anesthetics, IntravenousPhase 3, Phase 2, Phase 12406
36Antibiotics, AntitubercularPhase 3, Phase 2, Phase 16972
37AnestheticsPhase 3, Phase 2, Phase 19001
38Analgesics, OpioidPhase 33091
39Topoisomerase InhibitorsPhase 3, Phase 2, Phase 14945
40Adjuvants, AnesthesiaPhase 31588
41AnalgesicsPhase 311287
42Central Nervous System DepressantsPhase 3, Phase 2, Phase 112806
43Anti-Bacterial AgentsPhase 3, Phase 2, Phase 110884
44Contraceptive AgentsPhase 3, Phase 21901
45Contraceptives, OralPhase 31292
46Contraceptives, PostcoitalPhase 3169
47beta-endorphinPhase 3133
48Adrenocorticotropic HormonePhase 3, Phase 2155
49NarcoticsPhase 33486
50pancreatic polypeptidePhase 3, Phase 120

Interventional clinical trials:

(show top 50)    (show all 62)
idNameStatusNCT IDPhase
1Efficacy of Adjuvant Mitotane Treatment (ADIUVO)Unknown statusNCT00777244Phase 3
2A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical CarcinomaCompletedNCT00924989Phase 3
3Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)CompletedNCT00094497Phase 3
4Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
5An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00936741Phase 3
6A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00569582Phase 3
7European Low and Intermediate Risk Neuroblastoma ProtocolRecruitingNCT01728155Phase 3
8Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical TumorActive, not recruitingNCT00304070Phase 3
9Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal NeoplasiaNot yet recruitingNCT02010957Phase 2, Phase 3
10Sunitinib in Refractory Adrenocortical CarcinomaUnknown statusNCT00453895Phase 2
11Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer PatientsUnknown statusNCT00786110Phase 2
12Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland CancerUnknown statusNCT00003453Phase 2
13External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesUnknown statusNCT00637637Phase 2
14Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)CompletedNCT00215202Phase 2
15Trial With Taxotere and Cisplatin in Non-operable Adrenocortical CarcinomaCompletedNCT00324012Phase 2
16Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By SurgeryCompletedNCT00848016Phase 2
17A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical ResectionCompletedNCT00001339Phase 2
18Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical CancerCompletedNCT01255137Phase 2
19Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical CancerCompletedNCT00071058Phase 2
20A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsCompletedNCT01262235Phase 1, Phase 2
21Evaluation of 123I-Iodometomidate for Adrenal ScintigraphyCompletedNCT00454103Phase 1, Phase 2
22A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single AgentCompletedNCT00264433Phase 2
23Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2
24Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2
25Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
26RAD001 in Pheochromocytoma or Nonfunctioning CarcinoidCompletedNCT01152827Phase 2
27Surgery and Heated Chemotherapy for Adrenocortical CarcinomaRecruitingNCT01833832Phase 2
28Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical CarcinomaRecruitingNCT02673333Phase 2
29Nivolumab in Treating Patients With Metastatic Adrenocortical CancerRecruitingNCT02720484Phase 2
30Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeRecruitingNCT02468193Phase 2
31Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare TumorsRecruitingNCT02721732Phase 2
32Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
33Study to Evaluate CORT125134 in Patients With Cushing's SyndromeRecruitingNCT02804750Phase 2
34Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical CarcinomaActive, not recruitingNCT01514526Phase 2
35Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsNot yet recruitingNCT02867592Phase 2
36S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by SurgeryTerminatedNCT00002921Phase 2
37IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by SurgeryTerminatedNCT00778817Phase 2
38Treatment Study Using Bevacizumab for Patients With Adrenocortical CarcinomaWithdrawnNCT00469469Phase 2
39Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid TumorsCompletedNCT00003038Phase 1
40Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine FeaturesCompletedNCT01048892Phase 1
41Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
42Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal CancerCompletedNCT00436657Phase 1
43Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
44MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
45Spectroscopy With Surface Coils and DecouplingCompletedNCT00581815Phase 1
46Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical CarcinomaRecruitingNCT01898715Phase 1
47Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)RecruitingNCT01772004Phase 1
48A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni SyndromeActive, not recruitingNCT01981525Phase 1
49Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorNot yet recruitingNCT02831179Phase 1
50Possible New Therapy for Advanced CancerTerminatedNCT01832974Phase 1

Search NIH Clinical Center for Adrenal Cortical Carcinoma


Cochrane evidence based reviews: adrenocortical carcinoma

Genetic Tests for Adrenal Cortical Carcinoma

About this section

Genetic tests related to Adrenal Cortical Carcinoma:

id Genetic test Affiliating Genes
1 Adrenocortical Carcinoma, Hereditary27
2 Adrenocortical Carcinoma27
3 Adrenocortical Carcinoma, Pediatric27
4 Neoplasm of the Adrenal Cortex27

Anatomical Context for Adrenal Cortical Carcinoma

About this section

MalaCards organs/tissues related to Adrenal Cortical Carcinoma:

36
Cortex, Adrenal cortex, Adrenal gland, Lung, Breast, Liver, B cells

Publications for Adrenal Cortical Carcinoma

About this section

Articles related to Adrenal Cortical Carcinoma:

(show all 48)
idTitleAuthorsYear
1
Giant adrenal cortical carcinoma. (28065533)
2017
2
Metastatic adrenal cortical carcinoma to T12 vertebrae. (26765762)
2016
3
Nonislet Cell Tumor Hypoglycemia in a Patient with Adrenal Cortical Carcinoma. (27957352)
2016
4
Adrenal cortical carcinoma with tumor thrombus extension into the right atrium: A case report. (27313728)
2016
5
Clinicopathological Features Associated With the Prognosis of Patients With Adrenal Cortical Carcinoma: Usefulness of the Ki-67 Index. (27227935)
2016
6
Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma. (27857836)
2016
7
An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. (26685085)
2016
8
Mammary development, hyperestrogenemia, and hypocortisolemia in a male cat with an adrenal cortical carcinoma. (27708447)
2016
9
Peritoneal metastases from adrenal cortical carcinoma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (27716880)
2016
10
Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry. (26510907)
2015
11
Impact of Regional Lymph Node Dissection on Disease Specific Survival in Adrenal Cortical Carcinoma. (25938888)
2015
12
Epithelioid angiomyolipoma mimicking adrenal cortical carcinoma: A diagnostic pitfall. (26622807)
2015
13
Dominant" myelolipoma encasing adrenal cortical carcinoma: an unusual variation of myelolipoma occurring as a synchronous and predominant neoplasm. (24788531)
2014
14
Aldosterone and cortisol co-secreting bifunctional adrenal cortical carcinoma: A rare event. (25097323)
2014
15
Resection of giant adrenal cortical carcinoma: a case report. (25582906)
2014
16
Adrenal cortical carcinoma mimicking early severe preeclampsia. (27512421)
2014
17
Adrenal cortical adenoma with the maximal diameter greater than 5 cm: can they be differentiated from adrenal cortical carcinoma by CT? (25419344)
2014
18
Adrenal cortical carcinoma with extension into the inferior vena cava--case report and literature review. (24602387)
2014
19
A Mimic of Sarcomatoid Adrenal Cortical Carcinoma: Epithelioid Angiosarcoma Occurring in Adrenal Cortical Adenoma. (25246132)
2014
20
Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature. (24682757)
2014
21
Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. (24102952)
2014
22
Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. (24615603)
2014
23
Primary hyperaldostronisim as initial presentation of adrenal cortical carcinoma with liver metastasis: a case report. (24505527)
2013
24
Adrenal cortical carcinoma in Thailand: a review on the previous reported case. (24369210)
2013
25
Adrenal cortical carcinoma in a child, a rare cause of paediatric endocrinopathy: case report and literature review. (23025626)
2013
26
Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence. (23444945)
2013
27
Adrenal cortical carcinoma masquerading as pheochromocytoma: a case report. (23152728)
2012
28
Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. (22086150)
2012
29
Adrenal cortical carcinoma with late pulmonary metastases causing clinicical Cushing's syndrome: case report with immunohistochemical analysis of steriodogenic enzyme production. (22784838)
2012
30
Carney complex with adrenal cortical carcinoma. (22112809)
2012
31
Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure. (21648293)
2011
32
Myxoid adrenal cortical carcinoma presenting as primary hyperaldosteronism: case report and review of the literature. (20444728)
2011
33
Giant adrenal cortical carcinoma. (21196637)
2011
34
Myxoid adrenal cortical carcinoma--a rare variant of adrenocortical carcinoma. (16340152)
2005
35
Hyperaldosteronism and hyperprogesteronism in a cat with an adrenal cortical carcinoma. (15954552)
2005
36
Non-functioning adrenal cortical carcinoma presenting with metastasis to the tongue. (12581389)
2003
37
Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. (12472285)
2002
38
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. (12236151)
2002
39
Use of electron microscopic evaluation for the diagnosis of adrenal cortical carcinoma in fine needle aspiration cytology: a case report and review of the literature. (11793196)
2001
40
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. (11481490)
2001
41
Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma. (10509802)
1999
42
Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma. (7978053)
1994
43
Primary hyperaldosteronism: due to adrenal cortical carcinoma. (8323523)
1993
44
Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma. (1581233)
1992
45
Pure primary hyperaldosteronism due to adrenal cortical carcinoma. (4025371)
1985
46
Pure primary hyperaldosteronism due to adrenal cortical carcinoma. (6375367)
1984
47
Adrenal cortical carcinoma: an unusual cause of hyperaldosteronism. (6351990)
1983
48
In vivo and in vitro studies of steroid production by a luteoma and an adrenal cortical carcinoma in mice. (4304996)
1969

Variations for Adrenal Cortical Carcinoma

About this section

Clinvar genetic disease variations for Adrenal Cortical Carcinoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.1010G> A (p.Arg337His)SNVPathogenicrs121912664GRCh37Chr 17, 7574017: 7574017
2TP53NM_000546.5(TP53): c.854A> T (p.Glu285Val)SNVPathogenicrs121912667GRCh37Chr 17, 7577084: 7577084
3BMS1NM_014753.3(BMS1): c.2789G> A (p.Arg930His)SNVPathogenicrs587777706GRCh37Chr 10, 43315975: 43315975

Cosmic variations for Adrenal Cortical Carcinoma:

8 (show top 50)    (show all 64)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM10801TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.404G>Ap.C135Y8
2COSM4445249MEN1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.808C>Ap.L270M8
3COSM11071TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.1009C>Tp.R337C8
4COSM5664CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.121A>Gp.T41A8
5COSM44175TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.644G>Cp.S215T8
6COSM5667CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.134C>Tp.S45F8
7COSM5663CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.133T>Cp.S45P8
8COSM43931TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.523C>Ap.R175S8
9COSM4440759APCadrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.232G>Tp.D78Y8
10COSM4445248MEN1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.1132G>Tp.E378*8
11COSM10659TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.817C>Tp.R273C8
12COSM4445246MED12adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.4857G>Tp.K1619N8
13COSM4445247MEN1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.812G>Cp.G271A8
14COSM5672CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.94G>Ap.D32N8
15COSM11286TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.1015G>Tp.E339*8
16COSM5669CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,functioningc.98C>Tp.S33F8
17COSM4445245MED12adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.5576G>Ap.R1859H7
18COSM584NRASadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.182A>Gp.Q61R7
19COSM6815TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.461G>Tp.G154V7
20COSM28930EGFRadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.2354C>Ap.T785N7
21COSM27887GNASadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.601C>Tp.R201C7
22COSM51548APCadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.3234T>Ap.Y1078*7
23COSM10645TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.527G>Tp.C176F7
24COSM44083TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.1036G>Tp.E346*7
25COSM5693CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.118A>Gp.T40A7
26COSM43755TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.833C>Ap.P278H7
27COSM11245TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.430C>Tp.Q144*7
28COSM449BRAFadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.1391G>Ap.G464E7
29COSM13432EGFRadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.2193G>Ap.W731*7
30COSM326321RB1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.1994T>Gp.L665R7
31COSM10648TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.524G>Ap.R175H7
32COSM10790TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.455C>Tp.P152L7
33COSM30621CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.124A>Tp.T42S7
34COSM1561683MEN1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.125G>Ap.G42D7
35COSM4169851MSH2adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.1760-2A>Gp.?7
36COSM10725TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.701A>Gp.Y234C7
37COSM13198EGFRadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.2596G>Ap.E866K7
38COSM44623TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.487T>Ap.Y163N7
39COSM4445250MEN1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.1336C>Tp.R446C7
40COSM23054MEN1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.512G>Ap.R171Q7
41COSM44091TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.746G>Ap.R249K7
42COSM28929EGFRadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.2168T>Cp.F723S7
43COSM44816TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.667C>Tp.P223S7
44COSM13197EGFRadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.2590G>Ap.A864T7
45COSM476BRAFadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.1799T>Ap.V600E7
46COSM1355797MEN1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.989G>Ap.R330H7
47COSM574NRASadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.38G>Tp.G13V7
48COSM44288TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.452C>Tp.P151L7
49COSM28933NRASadrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.48A>Cp.K16N7
50COSM131449CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,NSc.1161T>Ap.N387K7

Copy number variations for Adrenal Cortical Carcinoma from CNVD:

6 (show all 23)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
139293101128521216864223DeletionAdrenocortical carcinoma
241923102603046227568983DeletionAdrenocortical carcinoma
369267125449695954887816AmplificationAdrenocortical carcinoma
4105388167919521480590034AmplificationAdrenocortical carcinoma
5105796168277421884680399AmplificationAdrenocortical carcinoma
6106027168517171186599633AmplificationAdrenocortical carcinoma
7106330168745581288254372AmplificationAdrenocortical carcinoma
8110643173380563434663603DeletionAdrenocortical carcinoma
9125811191535279816118051DeletionAdrenocortical carcinoma
10129302194510844845718366DeletionAdrenocortical carcinoma
11130528194953747050323207DeletionAdrenocortical carcinoma
12130657195035814353057498DeletionAdrenocortical carcinoma
13131131195321083253917176DeletionAdrenocortical carcinoma
141695733142987765144031265DeletionAdrenocortical carcinoma
1517608834653467147516603DeletionAdrenocortical carcinoma
1617657234968749050219610DeletionAdrenocortical carcinoma
1717705735243265653876467DeletionAdrenocortical carcinoma
1821637869115241095641352DeletionAdrenocortical carcinoma
192221967150275058151470304AmplificationAdrenocortical carcinoma
202357638144753570146201712DeletionAdrenocortical carcinoma
2123714982140865022539377DeletionAdrenocortical carcinoma
2223803382914751131607545DeletionAdrenocortical carcinoma
2323901883648103939128088DeletionAdrenocortical carcinoma

Expression for genes affiliated with Adrenal Cortical Carcinoma

About this section
Search GEO for disease gene expression data for Adrenal Cortical Carcinoma.

Pathways for genes affiliated with Adrenal Cortical Carcinoma

About this section

Pathways related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.4CYP11A1, MC2R, POMC
29.2CYP11A1, CYP17A1, CYP19A1, STAR
3
Show member pathways
9.2CYP11A1, CYP11B2, CYP21A2, MC2R, STAR
49.0CYP19A1, INHA, NR5A1
58.6CYP11A1, CYP11B1, CYP21A2, POMC, STAR
6
Show member pathways
8.3CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2
7
Show member pathways
7.4CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2

GO Terms for genes affiliated with Adrenal Cortical Carcinoma

About this section

Biological processes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1glucocorticoid metabolic processGO:000821110.7HSD11B2, STAR
2biphenyl metabolic processGO:001887910.7CYP17A1, STAR
3cellular response to antibioticGO:007123610.7CYP17A1, STAR
4cellular response to gonadotropin stimulusGO:007137110.7CYP17A1, STAR
5dibenzo-p-dioxin metabolic processGO:001889410.6CYP17A1, STAR
6regulation of blood volume by renal aldosteroneGO:000201710.6CYP11B2, HSD11B2
7mineralocorticoid biosynthetic processGO:000670510.6CYP11B2, CYP21A2
8Leydig cell differentiationGO:003332710.6CYP17A1, NR0B1
9phenol-containing compound metabolic processGO:001895810.6CYP17A1, STAR
10phthalate metabolic processGO:001896310.5CYP17A1, STAR
11regulation of steroid biosynthetic processGO:005081010.5NR5A1, STAR
12response to fungicideGO:006099210.5CYP17A1, STAR
13response to herbicideGO:000963510.5CYP17A1, STAR
14aldosterone biosynthetic processGO:003234210.5CYP11B1, CYP11B2
15response to insecticideGO:001708510.5CYP17A1, STAR
16cellular response to potassium ionGO:003586510.5CYP11B1, CYP11B2
17cortisol biosynthetic processGO:003465110.5CYP11B1, CYP11B2
18estrogen biosynthetic processGO:000670310.4CYP19A1, STAR
19cellular response to peptide hormone stimulusGO:007137510.3CYP11A1, CYP11B1, CYP11B2
20response to nutrient levelsGO:003166710.3CYP17A1, IGF2, STAR
21response to steroid hormoneGO:004854510.2CYP17A1, HSD11B2, STAR
22secondary metabolite biosynthetic processGO:004455010.1CYP11A1, CYP11B1, CYP11B2
23C21-steroid hormone biosynthetic processGO:000670010.0CYP11A1, CYP11B1, CYP11B2, STAR
24cholesterol metabolic processGO:000820310.0CYP11A1, CYP11B1, CYP11B2, STAR
25regulation of blood pressureGO:00082179.8CHGA, CYP11B1, POMC
26adrenal gland developmentGO:00303259.8CDKN1C, CYP17A1, NR0B1, NR5A1
27glucocorticoid biosynthetic processGO:00067049.8CYP11A1, CYP11B1, CYP17A1, CYP21A2, HSD11B2
28male gonad developmentGO:00085849.5INHA, NR0B1, NR5A1, STAR
29steroid biosynthetic processGO:00066949.1CYP17A1, CYP19A1, CYP21A2, NR0B1, STAR
30oxidation-reduction processGO:00551148.9CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2
31sterol metabolic processGO:00161258.5CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2

Molecular functions related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1corticosterone 18-monooxygenase activityGO:004778310.4CYP11B1, CYP11B2
2steroid 11-beta-monooxygenase activityGO:000450710.2CYP11B1, CYP11B2
3oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenGO:00167099.9CYP11A1, CYP11B1, CYP11B2
4steroid hydroxylase activityGO:00083959.4CYP11B2, CYP19A1, CYP21A2
5hormone activityGO:00051799.4IGF2, INHA, POMC
6heme bindingGO:00200379.1CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2
7iron ion bindingGO:00055069.0CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP21A2

Sources for Adrenal Cortical Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet